|Fields||Clinical Research, Molecular Imaging, Systems Biology|
|Institutions||Massachusetts General Hospital|
Professor Ralph Weissleder is an American clinician scientist.
Ralph Weissleder (born November 8, 1958 in Zell am Harmersbach, Germany) is a Professor at Harvard Medical School, Director of the Center for Systems Biology at Massachusetts General Hospital (MGH) and an Attending Interventional Radiologist at MGH.
Ralph Weissleder graduated from University of Heidelberg in 1985. Following his degrees, Dr. Weissleder completed an Internship and Residency at University Hospital, Monterrey, Mexico. In 1986, Dr. Weissleder moved to Boston (USA) where he pursued post-doctoral research (1986-1989) and then clinical training in radiology at Massachusetts General Hospital (MGH) and at Harvard Medical School (HMS). In 1994, Dr. Weissleder became Assistant Professor at HMS, Full Professor in 2001 (Department of Radiology), and remains an active physician at Massachusetts General Hospital. In 2007, Dr. Weissleder was appointed Director of the MGH Center for Systems Biology and in 2008, he was also appointed Professor in Systems Biology at HMS. Dr. Weissleder is a member of the Dana-Farber/Harvard Cancer Center and the Harvard Stem Cell Institute (HSCI).
Dr. Weissleder has received honorary degrees from The Universidad Autonoma de Nuevo León, Mexico (2007) and from Harvard University (2001).
Dr. Weissleder is a widely recognized and cited researcher in biotechnology, especially in the fields of imaging and next-gen diagnostics. His research interests include the development of novel molecular imaging techniques, tools for early disease detection as well as the development of nanomaterials for sensing and systems analysis. His research is translational in nature and several of his developments have led to commercialized technologies and advanced clinical trials. He is cofounder of T2 Biosystems, Lumicell, VisEn Medical (acquired by Perkin Elmer), and an advisor to several other biotech companies (Moderna, Alivio Therapeutics, Tarveda Therapeutics).
Dr. Weissleder’s practices at Massachusetts General Hospital which is widely recognized  for its patient care and ranks among the most accomplished and innovative medical institutions in the world. He is a faculty member of the Department of Radiology where his clinical specialty is in interventional radiology. He is a member of the Massachusetts General Physicians Organization. He has trained over 200 fellows.
Dr. Weissleder has published over 800 publications in peer reviewed journals, has authored and co-authored several textbooks and holds 27 patents. His work has been cited over 101,000 times and he has an h-index of 158.
Awards and honors
He is an elected member of the US National Academy of Medicine, the American Academy of Arts and Sciences and the German National Academy of Sciences (Leopoldina) His work has also been honored with numerous awards including the Millennium Pharmaceuticals Innovator Award (2003), the J. Taylor International Prize in Medicine (2004), the AUR Memorial Award, the ARRS President's Award, The Society for Molecular Imaging Lifetime Achievement Award, the Academy of Molecular Imaging 2006 Distinguished Basic Scientist Award, the 2008 RSNA Outstanding Researcher Award and the 2011 European Society of Radiology Gold Medal.
- Weissleder R, Schwaiger MC, Gambhir SS, Hricak H (2016). "Imaging approaches to optimize molecular therapies". Sci Transl Med. 8 (355): 355ps16. doi:10.1126/scitranslmed.aaf3936. PMID 27605550.
- Pucci F, Garris C, Lai CP, Newton A, Pfirschke C, Engblom C, Alvarez D, Sprachman M, Evavold C, Magnuson A, von Andrian UH, Glatz K, Breakefield XO, Mempel TR, Weissleder R, Pittet MJ (2016). "SCS macrophages suppress melanoma by restricting tumor-derived vesicle–B cell interactions". Science. 352 (6282): 242–246. doi:10.1126/science.aaf1328. PMID 26989197.
- Miller MA, Gadde S, Pfirschke C, Engblom C, Sprachman MM, Kohler RH, Yang KS, Laughney AM, Wojtkiewicz G, Kamal N, Bhonagiri S, Pittet MJ, Farokhzad OC, Weissleder R (2015). "Predicting therapeutic nano-medicine efficacy using a companion MR imaging nanoparticle". Sci Transl Med. 7 (314): 314ra183. doi:10.1126/scitranslmed.aac6522. PMID 26582898.
- Im H*, Shao H*, Park YI, Peterson VM, Castro CM, Weissleder R*, Lee H* (2014). "Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor". Nat Biotechnol. 32 (5): 490–5. doi:10.1038/nbt.2886. PMC . PMID 24752081.
- Weissleder R, Nahrendorf M, Pittet MJ (2014). "Imaging macrophages with nanoparticles". Nat Mater. 13 (2): 125–38. doi:10.1038/nmat3780. PMID 24452356.
- Laughney AM, Kim E, Sprachman MM, Miller MA, Kohler RH, Yang KS, Orth JD, Mitchison TJ, Weissleder R (2014). "Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin". Science Transl Med. 6 (261): 261ra152. doi:10.1126/scitranslmed.3009318. PMC . PMID 25378644.
- Ullal AV*, Peterson V*, Agasti SS, Tuang S, Juric D, Castro CM, Weissleder R (2014). "Cancer Cell Profiling by Barcoding Allows Multiplexed Protein Analysis in Fine-Needle Aspirates". Science Transl Med. 6 (219): 219ra9. doi:10.1126/scitranslmed.3007361. PMC . PMID 24431113.
- Haun JB*, Castro CM*, Wang R, Peterson VM, Marinelli BS, Lee H, Weissleder R. (2011). "MicroNMR Enables Rapid and Multiplexed Molecular Analysis of Scant Human Cancer Cells". Science Transl Med. 3 (71): 71ra16. doi:10.1126/scitranslmed.3002048. PMC . PMID 21346169.
- Swirski* FK, Nahrendorf* M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, Pittet MJ (2009). "Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites". Science. 325 (5940): 612–6. doi:10.1126/science.1175202. PMC . PMID 19644120.
- Weissleder R, Pittet MJ (April 2008). "Imaging in the era of molecular oncology". Nature. 452 (7187): 580–9. doi:10.1038/nature06917. PMC . PMID 18385732.
- Lee H, Sun E, Ham D, Weissleder R (August 2008). "Chip-NMR biosensor for detection and molecular analysis of cells". Nat. Med. 14 (8): 869–74. doi:10.1038/nm.1711. PMC . PMID 18607350.
- Weissleder R (May 2006). "Molecular imaging in cancer". Science. 312 (5777): 1168–71. doi:10.1126/science.1125949. PMID 16728630.
- Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L (November 2005). "Cell-specific targeting of nanoparticles by multivalent attachment of small molecules". Nat. Biotechnol. 23 (11): 1418–23. doi:10.1038/nbt1159. PMID 16244656.
- Harisinghani MG, Barentsz J, Hahn PF, et al. (June 2003). "Noninvasive detection of clinically occult lymph-node metastases in prostate cancer". N. Engl. J. Med. 348 (25): 2491–9. doi:10.1056/NEJMoa022749. PMID 12815134.
- Perez JM, Josephson L, O'Loughlin T, Högemann D, Weissleder R (August 2002). "Magnetic relaxation switches capable of sensing molecular interactions". Nat. Biotechnol. 20 (8): 816–20. doi:10.1038/nbt720. PMID 12134166.
- Bremer C, Tung CH, Weissleder R (June 2001). "In vivo molecular target assessment of matrix metalloproteinase inhibition". Nat. Med. 7 (6): 743–8. doi:10.1038/89126. PMID 11385514.
- Lewin M, Carlesso N, Tung CH, et al. (April 2000). "Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells". Nat. Biotechnol. 18 (4): 410–4. doi:10.1038/74464. PMID 10748521.
- Weissleder R, Tung CH, Mahmood U, Bogdanov A (April 1999). "In vivo imaging of tumors with protease-activated near-infrared fluorescent probes". Nat. Biotechnol. 17 (4): 375–8. doi:10.1038/7933. PMID 10207887.